PubMed Health⌕ Search

Biomedical subjects

T E Needham

Publications and source records attributed to T E Needham.

At least 19 recordsLinked to original sources

Development of a new non-surgical perfusion technique for evaluation of nasal drug delivery.

A new non-surgical perfusion technique was developed to evaluate nasal absorption using the rabbit as an animal model and insulin as a model drug. For these studies 20 ml of insulin solution (10 U/kg + 0.05% Na taurocholate) was perfused for 3.5 hours at a rate of 10 ml/hr. Spray formulations containing different levels of insulin (1.25, 2.5, 5 and 10 U/kg) and sodium taurocholate (0.05 and 1.0%) were evaluated in the same animal model. Insulin loaded polyacrylic acid microparticles were administered in 1% gel formulation to determine the comparative effect of insulin. The absorption of insulin was measured by glucose reduction. Pharmacodynamic parameters were determined relative to subcutaneously injected insulin (0.25 U/kg). The new non-surgical perfusion technique proved to be easier to control and more reproducible than the formerly used perfusion model while providing comparable results. The maximum relative absorption was observed for the 1.25 U/kg spray containing 1% NaTC. The polyacrylic acid gel formulation containing insulin loaded microparticles (10 U/kg) resulted in lower hypoglycemic effect compared to the spray formulations and subcutaneous injection.

Administration, Intranasal↗

Enhancement of nasal delivery of a renin inhibitor in the rat using emulsion formulations.

Nasal absorption of O-(N-morpholino-carbonyl-3-L-phenylaspartyl-L-leucinamide of (2S,3R,4S)-2-amino-1-cyclohexyl-3,4-dihydroxy-6-methylheptane (I), a renin inhibitor, was evaluated in two rat nasal models, one involving surgery and the other requiring no surgical intervention. Oleic acid/monoolein emulsion formulations were tested along with a control PEG 400 solution. The percent absolute bioavailability of the compound was enhanced from 3-6% (PEG 400 solution) to 15-27% when the emulsion formulations were used. The different nasal model techniques (with and without surgery) did not produce any statistical difference in the absolute bioavailability values for I. Emulsion formulations did not produce appreciable damage as assessed morphologically. It is suggested that emulsion formulations containing membrane adjuvants such as oleic acid and monoolein can be used to enhanced the nasal delivery of low-bioavailable, lipid-soluble drugs.

Administration, Intranasal↗

Oral delivery of a renin inhibitor compound using emulsion formulations.

The oral delivery of O-(N-morpholino-carbonyl-3-L-phenylaspartyl-L- leucinamide of (2S,3R,4S)-2-amino-1-cyclohexyl-3,4-dihydroxy-6-methylhetane (I), a new renin inhibitor, was studied in the in vivo rat model using emulsion formulations. The components of the emulsion formulations were chosen based on their proposed effects on membrane structure, membrane fluidity, and solute transport. The percent absolute bioavailability (%AB) of I was increased from 0.3% (water suspension) to 5.1% when long-chain unsaturated fatty acid (oleic acid, linoleic acid, etc.)- and mono- and diglyceride (monolein, dilaurin, etc.)-containing emulsion formulations were used. Considering very high first-pass liver extraction of the compound (80%), it is suggested that emulsion formulations increased the intestinal transport of the compound significantly. The solubility of I in aqueous media with and without bile salt (20 mM) was found to be low (approximately 1 micrograms/ml). Incubation in 0.01 N HCl did not affect the particle size of the emulsion. The titration of oleic acid/monoolein emulsion in a pH 6.5 medium with a mixed bile salt system indicated reduction in the particle size of the emulsion. Drug precipitation was observed above 30 mM bile salt concentrations. No drug crystals could be detected in the intestinal contents of the rats when emulsion formulations were ingested. These results suggest that in the intestine of the animals, the particle size of the emulsions is reduced in the presence of bile fluid while the drug resides primarily in the oil phase. The mechanism of enhanced transport of I from the emulsion formulations is discussed along with the possibility of cotransport for the drug and oil. Emulsion formulations can be a potential delivery form for low-bioavailable lipid-soluble drugs.

Absorption↗

Mechanism of misoprostol stabilization in hydroxypropyl methylcellulose.

The stability of misoprostol oil is significantly improved in a hydroxypropyl methylcellulose (HPMC) dispersion (1:100). In order to understand the enhanced stability of misoprostol oil in HPMC, the physical state of misoprostol oil in HPMC films was investigated using differential scanning calorimetry (DSC), dynamic mechanical analysis (DMA), and transmission IR (TIR). Further, to determine the effect of polymer structure and the mobility of both water and misoprostol on misoprostol stability, the rate of misoprostol degradation was investigated in the misoprostol/HPMC dispersion (1:100) at 55 degrees C. The water sorption isotherm of the dispersion at 55 degrees C was determined, at seven different relative humidities, ranging from zero to 81%. The DSC and DMA measurements indicated that misoprostol oil, up to 29% in dry weight, is molecularly dispersed in the glassy HPMC. The TIR studies showed no evidence of complexation between misoprostol and HPMC. Stability studies of the misoprostol/HPMC (1:100) dispersion indicated that the first-order rate constants for misoprostol degradation increased in a concave-up fashion as the water content of the dispersion increased. Below two percent water content, the rate of misoprostol degradation was found to be minimal. Overall, it is suggested that misoprostol is stabilized in the dispersion by being molecularly dispersed in HPMC. Further, the glassy state of HPMC should reduce the mobility of misoprostol and water, leading to a minimal rate of degradation for misoprostol at low moisture levels.

Calorimetry, Differential Scanning↗

Glass-rubber transitions of cellulosic polymers by dynamic mechanical analysis.

The glass-rubber transition temperatures (Tg) of several cellulosic polymers [hydroxypropyl methylcellulose (HPMC), hydroxypropyl cellulose (HPC), hydroxyethyl cellulose (HEC)] have been examined using dynamic mechanical analysis (DMA). The melting temperatures of the above polymers were examined using a hot stage melting point apparatus. The primary Tg of three different grades of HPMC (3, 6, and 15 cps) were determined to be 160, 170, and 175 degrees C, respectively. The primary Tg of the HEC film was determined as 120 degrees C. The HPC film did not indicate a primary Tg. These cellulosic polymers also displayed secondary transitions. Hot stage melting of HPMC and HPC was observed at 225 to 254 degrees C and 190 to 195 degrees C, respectively. The HEC powder did not exhibit a melting temperature, but became darker at temperatures greater than 150 degrees C.

Cellulose↗

Physical state of misoprostol in hydroxypropyl methylcellulose films.

Scanning electron (SEM) and light microscopy (LM), differential scanning calorimetry (DSC), and dynamic mechanical analysis (DMA) techniques were utilized to determine the miscibility of misoprostol and HPMC in the films with a misoprostol content from 0 to 29%, prepared using ethanol and methylene chloride/methanol (MeCl2/methanol, 50:50). Transmission infrared (TIR) analysis was used to look for evidence of any interaction between misoprostol and HPMC. The LM and SEM analysis of the ethanol cast films indicated no oil droplets. The DSC thermograms of the films showed no evidence of a -33 degrees C transition, which is characteristic of pure misoprostol. The DMA showed that the glass-rubber transition temperature (Tg) of the pure HPMC was lowered from 163 to 125-130 and 85-87 degrees C in the presence of 10 and 27-28% misoprostol. Based on these results it is suggested that misoprostol is solubilized in HPMC at concentrations up to 29%. The TIR analysis of the films showed no evidence of interaction between misoprostol and HPMC.

Alprostadil↗

Solid-state interaction of magnesium oxide and ibuprofen to form a salt.

During formulation development work involving ibuprofen, a solid-state interaction between MgO and ibuprofen was observed. In this study the interaction of MgO and ibuprofen was investigated for 1:1 and 2:1 M mixtures of ibuprofen and MgO, which had been stored at 55 degrees C, using the differential scanning calorimetric (DSC), thermogravic analysis (TGA), and multiple internal reflectance infrared (MIR) techniques. Evidence for the reaction was the disappearance of the melting endotherm at 79 degrees C and appearance of a new endotherm at 161 degrees C after less than 1 day of storage at 55 degrees C and, also, the change in the physical appearance of the mixtures. Comparison of the DSC, TGA, and MIR data for the reacted ibuprofen and MgO mixtures and synthetic Mg(ibuprofen)2 indicated that MgO and ibuprofen react to form the Mg salt of ibuprofen. The interaction of ibuprofen and MgO was also studied at 30 and 40 degrees C, using 1:1 M mixtures. At 30 degrees C no significant interaction was observed for up to 80 days; however, at 40 degrees C a reaction was evident on day 1. NaHCO3, K2CO3 1.5H2O, CaO, and Mg(OH)2 also showed solid-state reactions with ibuprofen. MgCl2 and Al(OH)3 did not show this reaction.

Calorimetry, Differential Scanning↗

Bioavailability of regular and controlled-release chlorpheniramine products.

The bioavailability of chlorpheniramine regular-release versus controlled-release products was compared using 15 human subjects. The dosage forms evaluated were an 8-mg barrier coated-bead capsule, an 8-mg repeat action tablet, two 4-mg tablets, and 4- and 8-mg syrups. Single doses of each product were administered orally in a 5-way crossover study, plasma samples were collected at specific time intervals, and chlorpheniramine levels assayed by HPLC. Pharmacokinetic analysis was based on a two-compartment open model. The average plasma elimination half-life of chlorpheniramine was calculated to be approximately 18.3 hr. The controlled-release products gave a higher Cmax than the 4-mg syrup, but less than two 4-mg tablets. The controlled-release products also extended the time necessary to attain peak drug levels compared to the 4- and 8-mg syrups. The area under the curve (AUC) data for the controlled-release products was not equivalent to equal amounts of the regular-release products. The study indicated that while the controlled-release chlorpheniramine products were successful in prolonging the time course of absorption, this was at the expense of incomplete bioavailability of the drug.

Adolescent↗

Plasma levels of clobazam after 10-, 20-, and 40-mg tablet doses in healthy subjects.

It is evident that substantial intersubject and intrasubject varition in the bioavailability of clobazam exists following ingestion of 10, 20 and 40 mg doses in these 12 volunteers. Peak concentrations and area under the plasma level-time curve were directly proportional to the dose of clobazam and the mean plasma half-life of clobazam was about 18 hours regardless of dose administered. The t1/2 value was less than that previously reported, as the current results allow differentiation of parent drug from metabolites. This 18 hr t1/2 compares favorably with the half-life of other benzodiazepines.

Adolescent↗

Bioavailability and dissolution parameters of seven lithium carbonate products.

Seven commercial products and a standard powder of lithium carbonate were administered to healthy human volunteers in a crossover study. An analysis of variance of saliva levels and urinary excretion as well as an analysis of variance of peak concentration and the area under the curve from 0 to 24 hr for the saliva levels showed no significant difference between the powder and products, but a significant difference between subjects. A significant difference was found between the time of peak saliva levels, which was attributed to faster powder absorption. A dissolution study using the USP basket method at 50 and 100 rpm and the Levy beaker at 50 rpm also showed no significant difference between products after the lag time for the capsule dosage forms. With a regression analysis, a significant correlation was found between the saliva levels of the products at 2 hr and dissolution in the USP basket at 50 rpm at 4 min.

Adult↗

Examination of blood clobazam levels and several pupillary measures in humans.

The State-Trait Anxiety Inventory was administered to 15 subjects before initiation of the experiment. Three subgroups of five subjects were defined by computing the unweighted sum of the state and trait anxiety scores. A 40-mg dose of clobazam, a 1.5-benzodiazepine, was administered to each subject and repeated with two additional dosage forms following a 2-week washout period. Blood samples were withdrawn, and blood levels were determined by fluorometric analysis. Additionally, pupillary measures of critical flicker fusion, constriction, and dilation in response to a cognitive task were obtained at 0, 2, 4, and 6 hr. A repeated measures analysis of variance revealed that blood levels were, as expected, statistically different over time and dosage form. The pupillary constriction mirrored the blood levels in statistical patterns. The pupillary measure of cognition related to the anxiety state after the performance effects of the cognitive task were statistically removed. The results suggest that clobazam has less immediate human effect than does diazepam.

Anxiety↗

Correlation of urinary excretion with in vitro dissolution using several dissolution methods for hydrochlorothiazide formulations.

Four different hydrochlorothiazide formulations were prepared, and cumulative urinary hydrochlorothiazide excretion was determined in a crossover study using six volunteers. A comparison of in vivo results showed that one formulation (Forumulation D) was significantly different from the others at 2, 3, 4, 5, 8, and 14 hr. A dissolution study was conducted on each formulation using the flask, USP basket, and magnetic basket methods at agitation speeds of 50, 100, and 150 rpm. Formulation D was significantly different from other formulations when determined using the USP basket method at 150 rpm and a sampling time of 10 min; the USP basket method at 100 rpm and a sampling time of 100 min; the flask method at 100 rpm and sampling times of 30, 40, 60, and 120 min; and the flask method at 150 rpm and sampling times of 30 and 40 min. Significant in vitro and in vivo correlations were found using a regression analysis and F test. With a correlation coefficient and 95% confidence intervals, it was established that the USP basket method at 150 rpm was the best predictor of urinary hydrochlorothiazide excretion among the dissolution methods tested.

Adult↗

Plasma levels of clobazam after three oral dosage forms in health subjects.

As can be seen from the tables, the terminal half-life of clobazam is about 50 hours, and from a solid dosage form the peak plasma level occurs approximately 1.5 hours after ingestion. Thus, there is a significant, yet relatively short, dosage form delay effect when the solid dosage forms are compared to the rapidly available solution of the drug. However, based on the areas under the curve, comparison of the solid dosage forms with the solution indicates that the fraction of clobazam absorbed is 1. Pupil diameter measurement at 2, 4, and 6 hours after ingestion of clobazam correlated well with the plasma levels at these times. Pupils were constricted to the highest degree at 2 hours and approached the initial pupillary diameter at the 6-hour measurement.

Administration, Oral↗

Correlation of aspirin excretion with parameters from different dissolution methods.

The cumulative urinary excretion of four different aspirin products (two tablets, a capsule, and a timed-release tablet) was determined in a crossover study using five subjects. Comparison of in vivo results showed a significant difference in cumulative urinary excretion levels at only 1 hr. The excretion from the two regular tablets was significantly different from the timed-release tablet, but the capsule showed no significant difference from the other three products. Each product was tested in the USP, Levy beaker, and the regular and large magnetic basket dissolution apparatus. Analysis of variance of the in vitro results showed a significant difference between the aspirin products and the dissolution methods at selected times. In vitro comparison with in vivo results for the four products showed that a regression analysis can be used to determined which dissolution methods produce a significant correlation with urinary excretion.

Adult↗

Interaction of sulindac and metabolite with human serum albumin.

The binding of the newly developed nonsteroidal anti-inflammatory agent sulindac and its principal active metabolite, sunlindac sulfide, to human serum albumin was investigated. With the methods of dialysis, fluorescence quenching, and difference spectrophotometry, it was found that both agents were extensively bound to albumin. The binding affinity of the metabolite was considerably higher than that of sunlindac and this effect may be related to its prolonged plasma half-life versus the parent drug. Sulindac binding was albumin concentration dependent, which gave rise to an unfamilar Scatchard analysis of the dialysis data.

Anti-Inflammatory Agents↗

Plasma level studies of penbutolol after oral dose in man.

Plasma levels of penbutolol (HOE 893d) were determined in eight healthy adult male subjects after oral administration of 50-mg capsules. Fast absorpiton of the drug from the gastrointestinal tract was indicated by the rapid increase in plasma levels during the absorption phase, with a peak time at about 1 hour after dosing in all subjects. After the peak level, plasma concentrations declined biexponentially, with an average half-life of 2.5 and 27 hours for the fast and slow disposition phases, respectively. These values were in good agreement with data previously found for this drug. Cumulative excretion of intact drug in the urine of the eight subjects during 72 hours after dosing was less than 4 per cent, except for one subject who excreted 9.82 per cent of the dose. Large individual variations were found for area under the plasma level curves, disposition rates, and amounts of intact drug excreted in the urine. Significant pharmacologic effects were noted in all eight subjects at the 50-mg dose level, and mild side effects were evident in one half of these subjects. The average drop in blood pressure and pulse rate for all subjects was 26/18 mm Hg and 19 beats per minute, respectively.

Administration, Oral↗